NL-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

NL-1 是一种 mitoNEET 抑制剂，具有抗白血病作用。

NL-1 is a mitoNEET inhibitor with antileukemic effect.

NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC50s of 29.48 μM, 94.26 μM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC50 values of around 60 μM for NL-1. NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells. Cell Proliferation Assay Cell Line:REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines Concentration:10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM Incubation Time:72 hours Result:Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner.Cell Autophagy Assay Cell Line:REH, REH/Ara-C cell lines Concentration:60 μM Incubation Time:6 hours Result:Induced cell autophagy.

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model. Animal Model:10 female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells Dosage:10 mg/kg Administration:Intraperitoneal injection; daily; for 5 days Result:Showed antileukemic activity in an in vivo mouse ALL model.

——

Autophagy

Autophagy

mitoNEET

——

——

188532-26-5

335.46

C18H25NO3S

>98% (HPLC)

DMSO:250 mg/mL (745.25 mM; Need ultrasonic)

CC(C)(C)c1cc(CC2SC(=O)NC2=O)cc(c1O)C(C)(C)C

——

(-20℃)

With Ice Pack

≥ 2 years